JMP Securities Begins Coverage on KalVista Pharmaceuticals (NASDAQ:KALV)

JMP Securities assumed coverage on shares of KalVista Pharmaceuticals (NASDAQ:KALV) in a research report released on Friday morning, MarketBeat.com reports. The brokerage issued an outperform rating and a $19.00 price objective on the specialty pharmaceutical company’s stock.

Other equities analysts have also issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of KalVista Pharmaceuticals in a report on Friday, December 6th. TD Cowen started coverage on shares of KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating and a $30.00 price objective for the company. Bank of America started coverage on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They set a “buy” rating and a $22.00 target price on the stock. Needham & Company LLC restated a “buy” rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a research note on Thursday, December 5th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, December 9th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $23.80.

KalVista Pharmaceuticals Price Performance

Shares of KalVista Pharmaceuticals stock opened at $8.91 on Friday. The firm has a fifty day moving average price of $8.83 and a 200 day moving average price of $10.84. The stock has a market cap of $440.31 million, a PE ratio of -2.45 and a beta of 0.86. KalVista Pharmaceuticals has a 1 year low of $7.30 and a 1 year high of $16.88.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.01. As a group, equities analysts expect that KalVista Pharmaceuticals will post -3.56 EPS for the current year.

Insider Activity at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 8,077 shares of the firm’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $9.26, for a total value of $74,793.02. Following the transaction, the insider now owns 94,199 shares in the company, valued at approximately $872,282.74. This trade represents a 7.90 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Benjamin L. Palleiko sold 7,627 shares of KalVista Pharmaceuticals stock in a transaction on Monday, December 9th. The stock was sold at an average price of $9.75, for a total transaction of $74,363.25. Following the sale, the chief executive officer now directly owns 274,596 shares in the company, valued at approximately $2,677,311. This trade represents a 2.70 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 32,291 shares of company stock valued at $304,086. 10.50% of the stock is owned by corporate insiders.

Institutional Trading of KalVista Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. Suvretta Capital Management LLC grew its position in shares of KalVista Pharmaceuticals by 0.5% in the third quarter. Suvretta Capital Management LLC now owns 4,212,005 shares of the specialty pharmaceutical company’s stock valued at $48,775,000 after purchasing an additional 20,000 shares in the last quarter. Vestal Point Capital LP grew its holdings in KalVista Pharmaceuticals by 73.9% in the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company’s stock valued at $46,320,000 after buying an additional 1,700,000 shares in the last quarter. State Street Corp increased its stake in shares of KalVista Pharmaceuticals by 68.1% in the 3rd quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock worth $14,725,000 after acquiring an additional 515,179 shares during the last quarter. Emerald Advisers LLC raised its holdings in shares of KalVista Pharmaceuticals by 29.8% during the 3rd quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company’s stock worth $9,681,000 after acquiring an additional 192,091 shares during the period. Finally, Geode Capital Management LLC raised its holdings in shares of KalVista Pharmaceuticals by 3.1% during the 3rd quarter. Geode Capital Management LLC now owns 830,984 shares of the specialty pharmaceutical company’s stock worth $9,624,000 after acquiring an additional 24,713 shares during the period.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).